Thomas W. Beetham's Net Worth
$10.1 Million
Who is Thomas W. Beetham?
Thomas W. Beetham has an estimated net worth of $10.1 Million. This is based on reported shares across multiple companies, which include Kiniksa Pharmaceuticals, Ltd., Magenta Therapeutics, Inc., and Viridian Therapeutics, Inc.\DE.
SEC CIK
Thomas W. Beetham's CIK is 0001741382
Past Insider Trading and Trends
2021 was Thomas W. Beetham's most active year for acquiring shares with 7 total transactions. Thomas W. Beetham's most active month to acquire stocks was the month of February. 2020 was Thomas W. Beetham's most active year for disposing of shares, totalling 8 transactions. Thomas W. Beetham's most active month to dispose stocks was the month of January. 2018 saw Thomas W. Beetham paying a total of $99,995.17 for 105,956 shares, this is the most they've acquired in one year. In 2020 Thomas W. Beetham cashed out on 107,093 shares for a total of $2,050,511.80, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Kiniksa Pharmaceuticals, Ltd. (KNSA) Snapshot price: $24.93
EVP & Chief Legal Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 16
| |||
Form 4
|
∞
| 297.52K |
$22.09 | -$54,716.93 | 297.52K |
Scheduled
|
Feb 3
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 10
| |||
Form 4
| -100.00% | -29.59K |
$25.37 | -$750,678.08 |
0
|
Scheduled
|
Jul 1
| ||
Form 4
|
—
|
0
|
$13.33 | -$322,896.96 | 29.59K |
Scheduled
|
Jun 10
| ||
Form 4
| -62.80% | -49.94K |
$19.10 | -$953,974.86 | 29.59K |
Scheduled
|
Apr 20 - Apr 21
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 13
| |||
Form 4
| -0.07% | -59.00 |
$18.58 | -$1,096.22 | 79.53K |
Scheduled
|
Feb 14
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 20
| |||
Form 4
| +8.73% | 6.39K |
—
|
—
| 79.59K |
Feb 9 - May 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Magenta Therapeutics, Inc. (DNTH) Snapshot price: $26.62
See Remarks
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +17.75% | 3K |
$0.94 | $2,820.00 | 19.9K |
Nov 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 1
| |||
Form 4
| +21.59% | 3K |
$0.99 | $2,970.00 | 16.9K |
May 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 4
| -30.51% | -6.10K |
$6.73 | -$41,073.19 | 13.9K |
Sep 16
| |||
Form 4
|
∞
| 20K |
—
|
—
| 20K |
Sep 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Viridian Therapeutics, Inc.\DE (VRDN) Snapshot price: $14.09
Chief Operating Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 30
| |||
| No matching records found | |||||||||